STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

Eligibility Criteria

• * Male or female patient ≥18 years old
• * Plan for treatment with an immune checkpoint inhibitor as standard of care even if patient is also on an additional investigational cancer therapeutic
• * Willingness to provide informed consent
• * Troponin T not available at screening or prior to randomization
• * Inability to comply with planned study procedures
• * Major adverse cardiovascular event included in the primary outcome within the 30 days prior to enrollment
• * Any medical condition that could interfere with, or for which the treatment might interfere with the conduct of the study or interpretation of the study results, or that would, in the opinion of the investigator, increase the risk of the participant by participating in the study
• * Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments.